AtriCure (ATRC) Scheduled to Post Earnings on Thursday

AtriCure (NASDAQ:ATRC) will be posting its quarterly earnings results after the market closes on Thursday, November 1st. Analysts expect AtriCure to post earnings of ($0.22) per share for the quarter.

ATRC stock opened at $31.00 on Wednesday. AtriCure has a one year low of $14.88 and a one year high of $36.49. The firm has a market capitalization of $1.04 billion, a PE ratio of -37.35 and a beta of 0.17. The company has a quick ratio of 2.37, a current ratio of 3.16 and a debt-to-equity ratio of 0.32.

In related news, SVP Justin J. Noznesky sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $30.32, for a total value of $121,280.00. Following the completion of the sale, the senior vice president now owns 124,920 shares in the company, valued at $3,787,574.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.70% of the stock is owned by company insiders.

Several analysts have recently commented on the stock. Canaccord Genuity raised their target price on shares of AtriCure from $37.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, October 9th. Zacks Investment Research upgraded shares of AtriCure from a “sell” rating to a “hold” rating in a research note on Friday, August 24th. Stifel Nicolaus raised their price objective on shares of AtriCure from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Thursday, August 2nd. BTIG Research reiterated a “hold” rating on shares of AtriCure in a research note on Thursday, August 2nd. Finally, ValuEngine upgraded shares of AtriCure from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 3rd. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $33.60.

AtriCure Company Profile

AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.

Featured Article: Leveraged Buyout (LBO) Explained

Earnings History for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply